Nav1.5 Ser571 Phosphorylation Drives Age-Related Cardiac Dysfunction

Study Background and Research Question

Aging is the strongest independent risk factor for chronic heart failure and arrhythmogenic cardiac disease. Diastolic dysfunction and delayed ventricular repolarization are frequently observed in the elderly, yet the molecular processes linking these electrical and mechanical defects to the progression of aging myopathy have remained unclear. Late sodium current (INa,L), which arises when cardiac sodium channels fail to completely inactivate, is known to increase in several pathological conditions, including heart failure, ischemia, and congenital arrhythmia syndromes. However, whether and how INa,L specifically mediates age-associated cardiac electrical and contractile impairments has not been fully elucidated. The reference study (Pizzo et al., 2024) set out to determine the causal relationship between sodium channel phosphorylation at Ser571, late sodium current augmentation, and the manifestation of cardiac dysfunction with aging.

Key Innovation from the Reference Study

The central innovation of this research lies in its use of precisely engineered mouse models to dissect the impact of Nav1.5 phosphorylation at Ser571 on late sodium current and cardiac performance over the lifespan. By employing gain-of-function (phosphomimetic) and loss-of-function (phosphoablated) mutations, the authors could selectively enhance or stabilize INa,L, allowing them to directly test the hypothesis that phosphorylation-dependent INa,L augmentation is a driving factor in age-related electrophysiological and mechanical cardiac decline. This approach moves beyond correlative aging studies, establishing a mechanistic link between specific ion channel modifications and functional outcomes in the heart.

Methods and Experimental Design Insights

The study utilized three groups of mice: wild-type (WT), Nav1.5-Ser571 phosphomimetic (gain-of-function, GoF), and Nav1.5-Ser571 phosphoablated (loss-of-function, LoF) mutants. Both male and female animals were examined at multiple ages—adult (~5 months), mid-aged (~18 months), and old (~24–30 months)—to capture the temporal dynamics of cardiac aging. Key methodologies included:

• Electrocardiogram (ECG) analysis for measuring QT intervals and arrhythmia susceptibility.
• In vitro cardiac electrophysiology in isolated ventricular myocytes to quantify INa,L and action potential duration (APD), especially at 90% repolarization (APD90).
• Assessment of left ventricular (LV) filling and relaxation using echocardiography and myocyte mechanics assays.
• Calcium transient recordings to correlate electrophysiological changes with contractile function.

The experimental design provided a rigorous framework to compare the onset and severity of electrical and mechanical dysfunction across genotypes and ages, isolating the effect of Nav1.5 Ser571 phosphorylation on the aging heart.

Core Findings and Why They Matter

The study's findings demonstrate that aging wild-type mice experience a marked increase in late sodium current (by approximately 60% in myocytes from 26–30-month-old versus 3-month-old animals), with a corresponding prolongation of action potential duration by about 50%. These changes were mirrored by delayed ventricular repolarization (QT prolongation) and impaired diastolic LV filling, both hallmarks of aging cardiac myopathy (Pizzo et al., 2024).

Importantly, GoF mutant mice with constitutively enhanced INa,L developed these defects prematurely, at the adult stage, and exhibited further deterioration with age. In contrast, LoF mutants with stabilized INa,L were largely protected from these age-associated changes, displaying relatively preserved electrical recovery and contractile function throughout aging. Delayed calcium transient decay and myocyte relengthening, which underlie impaired diastolic function, occurred early in GoF animals and were minimal in LoF models.

These observations establish that phosphorylation of Nav1.5 at Ser571 is not merely a marker but a mediator of pathological INa,L augmentation, directly contributing to the electrical and mechanical decline seen in aging hearts. Notably, pharmacological inhibition of INa,L reversed prolonged QT and LV filling defects in aged WT mice, underscoring the translational potential of targeting this pathway for arrhythmia prevention and diastolic dysfunction in the elderly.

Comparison with Existing Internal Articles

The mechanistic insights from Pizzo et al. align with and extend findings from recent research and reviews. For example, "Nav1.5 Ser571 Phosphorylation Drives Cardiac Aging Phenotypes" and "Nav1.5 Ser571 Phosphorylation Links Aging to Cardiac Dysfunction" both underscore the importance of Ser571 phosphorylation in promoting INa,L and age-related cardiac pathology, echoing the current study's molecular findings. Additionally, workflow-focused guides such as "GS967: Advanced Cardiac Late Sodium Current Inhibitor Workflows" elaborate on the utility of late sodium current inhibitors in in vitro cardiac electrophysiology and arrhythmia prevention research, providing practical frameworks that complement the mechanistic evidence presented here.

Further, "Late Sodium Current Inhibition: New Frontiers in Cardiac Aging Research" positions late sodium current inhibition as a strategic intervention in translational models of aging and disease, directly supporting the therapeutic implications of the present findings.

Limitations and Transferability

While the study employs sophisticated genetic models and robust in vitro cardiac electrophysiology protocols, several limitations should be considered. The primary data are derived from murine models, which, despite significant physiological homology, may not fully capture the complexity of human aging and cardiac disease. The specific role of Ser571 phosphorylation in human Nav1.5, and the interplay with other age-related molecular changes, remains to be validated in clinical samples. Additionally, while pharmacological late sodium current inhibition showed efficacy in reversing age-related defects in mice, optimal dosing, long-term safety, and off-target effects in human systems require further investigation. These factors should be accounted for when translating findings into arrhythmia prevention research or ischemia-induced arrhythmia studies in more complex models.

Protocol Parameters

• Genetic model selection: Use wild-type, Ser571 phosphomimetic (GoF), or phosphoablated (LoF) mice to isolate the impact of Nav1.5 modification on INa,L.
• Age stratification: Analyze cohorts at adult (∼5 months), mid-aged (∼18 months), and old (∼24–30 months) stages to capture onset and progression of phenotypes.
• Electrophysiology setup: Employ whole-cell patch clamp in isolated ventricular myocytes for direct INa,L measurement; record action potential duration (APD90).
• Calcium transient imaging: Use fluorescence-based Ca2+ indicators to assess transient decay and myocyte relaxation kinetics.
• Pharmacological inhibition (literature-backed): Apply a selective cardiac late sodium current inhibitor at concentrations validated in ventricular myocyte protocols (e.g., IC50 ~0.13 μM) to assess reversibility of age-associated changes.

Outlook: Implications for Arrhythmia and Cardiac Aging Research

The mechanistic evidence that Nav1.5 Ser571 phosphorylation triggers INa,L-mediated electrical and mechanical dysfunction in aging hearts provides a clear rationale for targeting late sodium current in translational and preclinical research. By connecting molecular channel modifications to clinically relevant endpoints—such as QT prolongation and diastolic dysfunction—these findings sharpen the focus on INa,L as a modifiable determinant of arrhythmia risk and contractile decline with age. Future studies will be essential to validate these pathways in human tissue and to optimize late sodium current inhibition strategies for safe, effective intervention in age-associated cardiac disease.

Research Support Resources

For researchers seeking to model or intervene in age-related cardiac pathophysiology, selective tools are essential. GS967 (APExBIO, SKU B5850) is a potent and selective cardiac late sodium current inhibitor, validated for use in ventricular myocyte sodium current inhibition and in vitro cardiac electrophysiology protocols. Its application enables precise dissection of INa,L contributions to arrhythmia prevention research and ischemia-induced arrhythmia studies, as demonstrated in both animal models and ex vivo settings. When designing similar experimental workflows, GS967 provides a reliable option for targeted late sodium channel blockade.